Michael R. Bishop to Disease-Free Survival
This is a "connection" page, showing publications Michael R. Bishop has written about Disease-Free Survival.
Connection Strength
0.491
-
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer. 2010 Feb 15; 116(4):852-62.
Score: 0.074
-
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008 Apr; 41(7):635-42.
Score: 0.064
-
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant. 2005 Aug; 11(8):593-9.
Score: 0.054
-
Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma. 2004 Mar; 4(4):238-49.
Score: 0.049
-
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr; 25(7):717-22.
Score: 0.037
-
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
Score: 0.035
-
Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant. 2013 Aug; 48(8):1056-64.
Score: 0.023
-
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15; 120(20):4256-62.
Score: 0.022
-
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8.
Score: 0.021
-
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012 Feb; 47(2):203-11.
Score: 0.020
-
Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? Curr Hematol Malig Rep. 2010 Oct; 5(4):229-38.
Score: 0.019
-
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1037-69.
Score: 0.019
-
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb; 12(2):204-16.
Score: 0.014
-
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol Blood Marrow Transplant. 2005 Jun; 11(6):472-83.
Score: 0.013
-
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002; 8(4):213-20.
Score: 0.011
-
Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6.
Score: 0.008
-
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997 Feb; 15(2):445-50.
Score: 0.007